Gets 7 Years of Orphan-drug Exclusive Approval from US FDA for Ryoncil

finance.yahoo.com/news/mesoblast-meso-gets-7-years-172842052.html

In This Article:
Mesoblast Limited (NASDAQ:MESO) is one of the 7 Best ASX Stocks to Buy Now. The company announced that it received 7 years of orphan-drug exclusive approval from the US FDA for Ryoncil® (remestemcel-L) for treating steroid-refractory acute graft versus host disease…

This story appeared on finance.yahoo.com, 2025-06-29 17:28:42.
The Entire Business World on a Single Page. Free to Use →